Biotech stocks continued to sway to the tunes of the broader market in the week ended Oct. 30, which succumbed to geopolitical and macroeconomic concerns.
Several big-name pharma companies, including Merck & Co. Inc. MRK 0.3% and Pfizer Inc. PFE 0.08%, reported earnings during the week. The earnings news flow was broadly mixed.
Catabasis Pharmaceuticals Inc CATB 1.47% was among the biggest decliners, as it halted a late-stage trial of its Duchenne muscular dystrophy drug.
On the other hand, Scholar Rock Holding Corp. SRRK 8.11% was up about over 175% during the week, reacting to positive mid-stage results for spinal muscular atrophy drug.
On the COVID-19 front, Regeneron Pharmaceuticals Inc. said it is REGN 1.57% halting the Phase 3 trial of its antibody cocktail in patients with severe COVID-19, citing safety issue.
Kala Pharmaceuticals Inc. KALA 2.67% announced FDA approval for its dry eye disease drug, while Spectrum Pharmaceuticals Inc. SPPI 2.58% communicated a delay in the decision for its treatment option for chemotherapy-induced neutropenia, as the FDA could not inspect a plant in South Korea due to COVID-19.
Here're the key catalysts for the unfolding week:
Conferences
- International Cytokine and Interferon Society's Cytokines, or, ICIS, 2020 Conference – Nov. 1–5
- 13th Clinical Trials on Alzheimer's Disease, or CTAD: Nov. 4-7
Adcom Calendar
FDA's Peripheral and Central Nervous System Drugs Advisory Committee will discuss Friday Biogen Inc's BIIB 0.8% BLA for its Alzheimer's treatment candidate aducanumab. On Nov. 4, the FDA will release briefing document that has the potential to move the stock.
Outperformance of Biogen hinges on a positive regulatory verdict for aducanumab, according to SVB Leerink analyst Marc Goodman.
Clinical Readouts/Presentations
Surface Oncology Inc. SURF 5.58% is scheduled to present at the ICIS congress, preclinical data on SRF388, a first in class IL-27 blocking antibody, in clinical trials for patients with cancer. (Sunday. 5:30 pm-7:30 pm)
vTv Therapeutics Inc. VTVT 2.89% will make an oral presentation at the CTAD, providing a general study update and data on the baseline characteristics of patients enrolled in the ongoing phase 2 Elevage Study of azeliragon as a potential treatment for mild-probable Alzheimer's disease in adult patients who also have type 2 diabetes. (Wednesday, 1am)
Bellerophon Therapeutics Inc. BLPH 2.2% will present at the American Thoracic Society Interstitial Lung Disease Mini Symposia as well as the 2020 Pulmonary Fibrosis Foundation Meeting, data from its Phase 2 study of INOpulse for the treatment of fibrotic interstitial lung disease patients at risk for pulmonary hypertension. (Thursday)
Cassava Sciences Inc. SAVA 2.91% is due to present at the CTAD conference, results of its Phase 2b study of sumifilam in Alzheimer's disease. (Saturday, 11:10 am)
Earnings
Monday
- IVERIC bio Inc. ISEE 1.5% (before the market open)
- Eagle Pharmaceuticals Inc. EGRX 1.77% (before the market open)
- Intersect ENT Inc XENT 2.76% (before the market open)
- Horizon Therapeutics PLC HZNP 0.3% (before the market open)
- Minerva Neurosciences Inc NERV 0.65% (before the market open)
- Jazz Pharmaceuticals PLC JAZZ 0.95% (after the close)
- Neuronetics Inc STIM 9.39% (before the market open)
- Inspire Medical Systems Inc INSP 32.24% (before the market open)
- Veracyte Inc VCYT 9.2% (before the market open)
- Syndax Pharmaceuticals Inc. SNDX 10.88% (before the market open)
- Halozyme Therapeutics Inc. HALO 11.34% (before the market open)
- Esperion Therapeutics Inc. ESPR 16.52% (before the market open)
- Urovant Sciences Ltd. UROV 6.73% (before the market open)
- DURECT Corporation DRRX 6.78% (before the market open)
- SI-Bone Inc SIBN 4.49% (before the market open)
- Karyopharm Therapeutics (Inc NASDAQ: KPTI)
- Pacific Biosciences of California Inc PACB 4.08%
Tuesday
- Oxford Immunotec Global PLC OXFD 14.25% (before the market open)
- Catalent Inc CTLT 7.91% (before the market open)
- Avanos Medical Inc. AVNS 8.65% (before the market open)
- Acorda Therapeutics Inc. ACOR 1.82% (after the close)
- Five Prime Therapeutics Inc. FPRX 3.88% (after the close)
- GW Pharmaceuticals PLC- ADR GWPH 21.19% (after the close)
- Supernus Pharmaceuticals Inc. SUPN 1.2% (after the close)
Related Link: Aldeyra Has 'Catalayst-Rich' 12 Months Ahead, Jefferies Says In Bullish Initiation
Wednesday
- Haemonetics Corp. HAE 0.58% (before the market open)
- Aquestive Therapeutics Inc. AQST 10.42% (after the close)
- Anika Therapeutics Inc. ANIK 5.8% (after the close)
- Axonics Modulation Technologies Inc. AXNX 6.01% (after the close)
- ACADIA Pharmaceuticals Inc. ACAD 2.1% (after the close)
- T2 Biosystems Inc. TTOO 2.27% (after the close)
- OraSure Technologies, Inc. OSUR 0.64% (after the close)
- Hologic Inc. HOLX 1.93% (after the close)
- Otonomy Inc. OTIC 1.44% (after the close)
- SurModics Inc. SRDX 1.17% (after the close)
- Sangamo Therapeutics Inc. SGMO 2.6% (after the close)
- PRA Health Sciences Inc. PRAH 3.63% (after the close)
- Cytosorbents Corp. CTSO 7.21% (after the close)
- Lineage Cell Therapeutics Inc. LCTX 4.7% (after the close)
- Insulet Corp. PODD 3.3% (after the close)
- Cytokinetics Inc. CYTK 4.83% (after the close)
- MannKind Corp. MNKD 2.5% (after the close)
- Flexion Therapeutics Inc. FLXN 0.17% (after the close)
- DiaMedica Therapeutics Inc. DMAC 4.09% (after the close)
- Orthopediatrics Corp. KIDS 3.79%)
- Ionis Pharmaceuticals Inc. IONS 0.49%
- G1 Therapeutics Inc. GTHX 3.39%
- Spectrum Pharmaceuticals Inc. SPPI 2.58%
Thursday
- Kura Oncology Inc. KURA 6.31% (before the market open)
- Synlogic Inc. SYBX 0.54% (before the market open)
- Regeneron (before the market open)
- Bristol-Myers Squibb Co. BMY 2.94% (before the market open)
- Arbutus Biopharma Corp. ABUS 4.71% (before the market open)
- Alnylam Pharmaceuticals Inc. ALNY 3.31% (before the market open)
- Athenex Inc ATNX 3.55% (before the market open)
- Adaptimmune Therapeutics PLC – ADR ADAP 1.55% (before the market open)
- ANI Pharmaceuticals Inc Common Stock ANIP 2.22% (before the market open)
- Antares Pharma Inc. ATRS 6.07% (before the market open)
- Agios Pharmaceuticals Inc. AGIO 3.26% (before the market open)
- X4 Pharmaceuticals Inc. XFOR 4.68% (before the market open)
- SAGE Therapeutics Inc. SAGE 3.56% (before the market open)
- Intellia Therapeutics Inc. NTLA 3.91% (before the market open)
- Kala Pharmaceuticals Inc. KALA 2.67% (before the market open)
- OptiNose Inc. OPTN 6.55% (before the market open)
- Orthofix Medical Inc. OFIX 3% (before the market open)
- Radius Health Inc RDUS 0.46% (before the market open)
- Repligen Corp. RGEN 4.63% (before the market open)
- Incyte Corp. INCY 0.6% (before the market open)
- Eyepoint Pharmaceuticals Inc. EYPT 2.97% (before the market open)
- Concert Pharmaceuticals Inc. CNCE 2.97% (before the market open)
- Clovis Oncology Inc. CLVS 5.44% (before the market open)
- Vericel Corp. VCEL 9.64% (before the market open)
- Provention Bio Inc. PRVB 4.51% (before the market open)
- Harvard Bioscience Inc. HBIO 7.8% (before the market open)
- BioCryst Pharmaceuticals, Inc. BCRX 2.73% (before the market open)
- BioDelivery Sciences International, Inc. BDSI 3.42% (before the market open)
- Amarin Corporation plc AMRN 1.01% (before the market open)
- Y-mAbs Therapeutics Inc. YMAB 2.7% (after the close)
- AcelRx Pharmaceuticals Inc. ACRX 0.55% (after the close)
- Aerie Pharmaceuticals Inc. AERI 0.82% (after the close)
- Adamas Pharmaceuticals Inc. ADMS 2.65% (after the close)
- Transenterix Inc. TRXC 0.6% (after the close)
- Paratek Pharmaceuticals Inc. PRTK 1.75% (after the close)
- Nektar Therapeutics NKTR 2.17% (after the close)
- Spero Therapeutics Inc. SPRO 8.02% (after the close)
- Misonix Inc. MSON 1.93% (after the close)
- TFF Pharmaceuticals Inc TFFP 3.61% (after the close)
- Xencor Inc XNCR 4.51% (after the close)
- Oyster Point Pharma Inc. OYST 1.78% (after the close)
- Sarepta Therapeutics Inc. SRPT 2.95% (after the close)
- Natera Inc. NTRA 5.89% (after the close)
- ICU Medical Inc. ICUI 3.11% (after the close)
- Rigel Pharmaceuticals, Inc. RIGL 2% (after the close)
- Guardant Health Inc GH 2.47% (after the close)
- Retrophin Inc RTRX 2.93% (after the close)
- Tandem Diabetes Care Inc TNDM 4.69% (after the close)
- Chembio Diagnostics Inc CEMI 1.51% (after the close)
- Dicerna Pharmaceuticals Inc DRNA 2.84% (after the close)
- Exelixis, Inc. EXEL 2.33% (after the close)
- Endo International PLC ENDP 2.86% (after the close)
- FibroGen Inc FGEN 2.09% (after the close)
- Fluidigm Corporation FLDM 6.95% (after the close)
- Nevro Corp NVRO 2.53% (after the close)
- CytomX Therapeutics Inc CTMX 2.67% (after the close)
- Dynavax Technologies Corporation DVAX 6.38% (after the close)
- Geron Corporation GERN 2.29% (after the close)
- CorMedix Inc. CRMD 8.43% (after the close)
- Celcuity Inc CELC (after the close)
- BioLife Solutions Inc BLFS 4.57% (after the close)
- Caladrius Biosciences Inc CLBS 4.64% (after the close)
- Theravance Biopharma Inc TBPH 1.29% (after the close)
- Global Blood Therapeutics Inc GBT 2.9% (after the close)
- Coherus Biosciences Inc CHRS 2.89% (after the close)
- Iovance Biotherapeutics Inc IOVA 1.81%
- AtriCure Inc. ATRC 5.8%
- Acceleron Pharma Inc XLRN 1.6%
- ADMA Biologics Inc ADMA
- Ocular Therapeutix Inc OCUL 0.66%
- Ironwood Pharmaceuticals, Inc. IRWD 1.95%
- Syros Pharmaceuticals Inc SYRS 9.86%
- ZIOPHARM Oncology Inc. ZIOP
- Sensus Healthcare Inc SRTS 1.24%
- Deciphera Pharmaceuticals Inc DCPH 4.73%
- Eloxx Pharmaceuticals Inc ELOX 8.68%
- Chiasma Inc CHMA 0.54%
- Emergent Biosolutions Inc EBS 1.91%
- INmune Bio Inc INMB 7.72%
- Calithera Biosciences Inc CALA 1.15%
Friday
- Mylan NV MYL (before the market open)
- Amphastar Pharmaceuticals Inc AMPH 2.36% (before the market open)
- Amneal Pharmaceuticals Inc AMRX 2.46% (before the market open)
- Elanco Animal Health Inc ELAN 1.82% (before the market open)
- Matinas BioPharma Holdings Inc MTNB 0.24% (before the market open)
- Zimmer Biomet Holdings Inc ZBH 3% (before the market open)
IPO Analysts' Quiet Period Expiry
- Aziyo Biologics Inc AZYO 4.26%
- Kronos Bio Inc KRON 0.93%
- Spruce Biosciences Inc SPRB 4.33%
- https://www.benzinga.com/general/biotech/20/11/18157255/the-week-ahead-in-biotech-nov-1-7-adcom-test-for-biogens-aducanumab-alzheimers-conference-smid-ca
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.